Antitumor agents. 100. Inhibition of human DNA topoisomerase II by cytotoxic ether and ester derivatives of podophyllotoxin and .alpha.-peltatin
- 1 March 1989
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 32 (3) , 604-608
- https://doi.org/10.1021/jm00123a016
Abstract
A principal mechanism of action of the clinical antitumor drugs etoposide (1) and teniposide (2) is the inhibition of catalytic activity of type II DNA topoisomerase and concurrent enzyme-mediated production of lethal DNA strand breaks. Substitution of the glycosidic moiety of 1 or 2 by ester and ethers, as well as the esterification and etherification of .alpha.-peltatin (4) including its glucosidic ethylidene and thenylidene cyclic acetals (25 and 26), has afforded compounds of much less activity than that of 1. The in vitro cytotoxicity (KB) appears to have no correlation with the inhibitory activity of the human DNA topoisomerase II.This publication has 6 references indexed in Scilit:
- Antitumor agents. 78. Inhibition of human DNA topoisomerase II by podophyllotoxin and .alpha.-peltatin analogsJournal of Medicinal Chemistry, 1986
- Purification and characterization of a type II DNA topoisomerase from bovine calf thymus.Journal of Biological Chemistry, 1985
- Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.Journal of Biological Chemistry, 1984
- The purification and characterization of DNA topoisomerases I and II of the yeast Saccharomyces cerevisiae.Journal of Biological Chemistry, 1984
- Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26Biochemical and Biophysical Research Communications, 1984
- Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.Proceedings of the National Academy of Sciences, 1984